BIOSUN PHARMA

BIOSUN PHARMA is an innovative biopharmaceutical company located in the Liangzhu International Life Science and Technology Town, Yuhang District. It was co-founded by senior executives from domestic listed companies and seasoned overseas returnee drug development experts. The company is dedicated to the development of FIC and/or BIC drugs in the fields of oncology, immunology, and inflammation. With a focus on meeting clinical needs, BIOSUN PHARMA seeks differentiated development in terms of targets and indications, aiming to be "small and beautiful" rather than "large and comprehensive," with the goal of developing distinctive products and avoiding homogenized competition in targets or indications. Since its establishment, the company has built technology platforms, R&D systems, and talent pipelines covering both large and small molecule drugs, with a rich product pipeline. Two products have entered clinical research, among which the company's self-developed JAK inhibitor—Bangrotinib—has advanced to Phase II/III registrational clinical trials, showing broad application prospects in myeloproliferative neoplasms and autoimmune diseases. In the next three years, it is expected that more indications will enter late-stage clinical research, additional R&D products will move into clinical trials, and the company will also step into the industrialization phase.